Hepatocyte transplantation for inherited metabolic diseases of the liver

J Intern Med. 2012 Sep;272(3):201-23. doi: 10.1111/j.1365-2796.2012.02574.x. Epub 2012 Aug 20.

Abstract

Inherited metabolic diseases of the liver are characterized by deficiency of a hepatic enzyme or protein often resulting in life-threatening disease. The remaining liver function is usually normal. For most patients, treatment consists of supportive therapy, and the only curative option is liver transplantation. Hepatocyte transplantation is a promising therapy for patients with inherited metabolic liver diseases, which offers a less invasive and fully reversible approach. Procedure-related complications are rare. Here, we review the experience of hepatocyte transplantation for metabolic liver diseases and discuss the major obstacles that need to be overcome to establish hepatocyte transplantation as a reliable treatment option in the clinic.

Trial registration: ClinicalTrials.gov NCT01345578.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptive Immunity
  • Animals
  • Cell Culture Techniques
  • Cell Transplantation / methods*
  • Cellular Senescence
  • Cryopreservation
  • Hepatocytes / cytology*
  • Humans
  • Immunity, Innate
  • Immunosuppression Therapy
  • Liver Diseases / therapy*
  • Metabolism, Inborn Errors / therapy*
  • Tissue Donors
  • Transplantation Conditioning

Associated data

  • ClinicalTrials.gov/NCT01345578